| Gene | [TLR4](/genes/tlr4) |
| UniProt | [O00206](https://www.uniprot.org/uniprot/O00206) |
| MW | 95 kDa |
| Location | Cell membrane, endosomes |
| PDB | [3FXI](https://www.rcsb.org/structure/3FXI) |
Toll-like receptor 4 (TLR4) is a pattern recognition receptor that serves as the primary sensor for bacterial lipopolysaccharide (LPS). Expressed on microglia, astrocytes, and peripheral immune cells, TLR4 triggers innate immune responses through MyD88-dependent and TRIF-dependent signaling pathways. In the CNS, TLR4 mediates neuroinflammation and has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
TLR4 is a type I transmembrane receptor with:
TLR4 forms a complex with MD-2 (LY96) at the cell surface:
TLR4 detects gram-negative bacterial infections:
TLR4 activates two distinct pathways:
| Pathway | Adaptor | Outcome |
|---|---|---|
| MyD88-dependent | MyD88, TIRAP | Early NF-κB activation, pro-inflammatory cytokines |
| TRIF-dependent | TRIF, TRAM | Late NF-κB, IRF3 activation, type I interferons |
TLR4 contributes to AD pathogenesis through multiple mechanisms:
Animal studies: TLR4 deficiency accelerates Aβ deposition, suggesting a complex role with both protective and detrimental effects[2].
TLR4 is implicated in dopaminergic neuron degeneration:
TLR4 expression is elevated in ALS:
TLR4 mediates post-traumatic neuroinflammation:
Several strategies target TLR4 in neurodegeneration:
| Agent | Mechanism | Status |
|---|---|---|
| TAK-242 (Resatorvid) | Binds TIR domain, blocks signaling | Preclinical/clinical trials |
| Eritoran | MD-2 antagonist, prevents LPS binding | Phase III (sepsis), preclinical (neuro) |
| E5564 | Synthetic lipid A analogue | Clinical development |
| Natural antagonists | Curcumin, resveratrol | Dietary supplements |
TLR4 inhibition may synergize with other approaches:
| Partner | Function | Disease Relevance |
|---|---|---|
| MD-2 (LY96) | LPS co-receptor | Required for signaling |
| CD14 | LPS presentation | Enhances sensitivity |
| MyD88 | Signal adaptor | NF-κB activation |
| TRIF | Signal adaptor | IRF3/interferon |
| HMGB1 | Endogenous DAMP | Neurodegeneration |
| α-synuclein | Protein aggregate | PD neuroinflammation |
TLR4 polymorphisms influence neurodegenerative disease risk:
Tahara et al. TLR4 signaling pathways in Alzheimer's disease. Neurochem Int. 2014;75:19-26.
Tang et al. Toll-like receptor 4 deficiency impairs microglial activation and delays amyloid plaque formation. J Neuroinflammation. 2007;4:40.
Stefanova et al. α-synuclein activates TLR4-dependent microglial inflammatory responses. J Neuroinflammation. 2011;8:138.
Bi et al. Association of TLR4 polymorphisms with sporadic Alzheimer's disease in a Chinese Han population. J Neuroinflammation. 2019;16(1):25.
Fassbender et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 2004. ↩︎
Landreth et al. Inflammation in Alzheimer's disease and therapeutic implications. Mol Cell Neurosci. 2018. ↩︎
Kim et al. α-Synuclein induces activation of microglia via TLR4 and NF-κB signaling. J Neuroinflammation. 2011. ↩︎
Balistreri et al. TLR4 polymorphisms and environment: implications for neurodegenerative diseases. Autoimmun Rev. 2013. ↩︎